Literature DB >> 23792471

An update on HDV: virology, pathogenesis and treatment.

Mónica V Alvarado-Mora1, Stephen Locarnini, Mario Rizzetto, João R Rebello Pinho.   

Abstract

Hepatitis delta is an inflammatory liver disease caused by infection with HDV. HDV is a single-stranded circular RNA pathogen with a diameter of 36 nm. HDV is classified in the genus Deltavirus and is still awaiting a final taxonomic classification up to the family level. HDV shares similarities with satellite RNA and viroids including a small circular single-stranded RNA with secondary structure that replicates through the 'double rolling circle' mechanism. The HDV RNA genome is capable of self-cleavage through a ribozyme and encodes only one structural protein, the hepatitis delta antigen (HDAg), from the antigenomic RNA. There are two forms of HDAg, a shorter (S; 22 kDa) and a longer (L; 24 kDa) form, the latter generated from an RNA editing mechanism. The S form is essential for viral genomic replication. The L form participates in the assembly and formation of HDV. For complete replication and transmission, HDV requires the hepatitis B surface antigen (HBsAg). Thus, HDV infection only occurs in HBsAg-positive individuals, either as acute coinfection in treatment-naive HBV-infected persons, or as superinfection in patients with pre-existing chronic hepatitis B (CHB). HDV is found throughout the world, but its prevalence, incidence, clinical features and epidemiological characteristics vary by geographic region. There are eight genotypes (1 to 8) distributed over different geographic areas: HDV-1 is distributed worldwide, whereas HDV-2 to 8 are seen more regionally. Levels of HDV viraemia change over the course of HDV infection, being significantly higher in patients with early chronic hepatitis than in cirrhosis. Chronic HDV infection leads to more severe liver disease than chronic HBV monoinfection with an accelerated course of fibrosis progression, an increased risk of hepatocellular carcinoma and early decompensation in the setting of established cirrhosis. Current treatments include pegylated interferon-α and liver transplantation; the latter of which can be curative. Further studies are needed to develop better treatment strategies for this challenging disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23792471     DOI: 10.3851/IMP2598

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  27 in total

1.  Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.

Authors:  Ashish Goyal; John M Murray
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

Review 2.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

3.  Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification.

Authors:  Maria Homs; Katja Giersch; Maria Blasi; Marc Lütgehetmann; Maria Buti; Rafael Esteban; Maura Dandri; Francisco Rodriguez-Frias
Journal:  J Clin Microbiol       Date:  2014-07-02       Impact factor: 5.948

Review 4.  Viral hepatitis and pregnancy.

Authors:  Norah A Terrault; Miriam T Levy; Ka Wang Cheung; Gonzague Jourdain
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-12       Impact factor: 46.802

Review 5.  Recent breakthroughs in the treatment of chronic hepatitis Delta.

Authors:  Giuseppina Brancaccio; Laura Gaeta; Alessandro Vitale; Giovanni B Gaeta
Journal:  Infez Med       Date:  2022-06-01

Review 6.  Beyond Metabolism: Role of the Immune System in Hepatic Toxicity.

Authors:  Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson
Journal:  Int J Toxicol       Date:  2020 Mar/Apr       Impact factor: 2.032

Review 7.  Discriminating Self and Non-Self by RNA: Roles for RNA Structure, Misfolding, and Modification in Regulating the Innate Immune Sensor PKR.

Authors:  Chelsea M Hull; Philip C Bevilacqua
Journal:  Acc Chem Res       Date:  2016-06-08       Impact factor: 22.384

Review 8.  Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Mariantonietta Pisaturo; Margherita Macera; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 9.  Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions.

Authors:  Rafael Aldabe; Lester Suárez-Amarán; Carla Usai; Gloria González-Aseguinolaza
Journal:  Pathogens       Date:  2015-02-12

Review 10.  Quantification of liver fibrosis in chronic hepatitis B virus infection.

Authors:  C F Jieanu; B S Ungureanu; D L Săndulescu; I A Gheonea; D R Tudorașcu; M E Ciurea; V L Purcărea
Journal:  J Med Life       Date:  2015 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.